Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette Alaeus

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Scandinavian Journal of Infectious Diseases|November 20, 2009
HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatmentKarolin Falconer, Johan K Sandberg, Olle Reichard, et al.
AIDS Research and Human Retroviruses|December 18, 2003
Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AEIrina Maljkovic, Karin Wilbe, Ellen Sölver, et al.
Scandinavian Journal of Infectious Diseases|September 30, 2003
Chronic hepatitis C: updated Swedish consensusRune Wejstål, Annette Alaeus, Björn Fischler, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 21, 2007
Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell functionKarolin Falconer, Veronica D Gonzalez, Olle Reichard, et al.
Scandinavian Journal of Infectious Diseases|July 9, 2010
IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIVKarolin Falconer, Galia Askarieh, Nina Weis, et al.
AIDS Research and Human Retroviruses|March 30, 2005
Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapyAnn Atlas, Fredrik Granath, Anna Lindström, et al.
Scandinavian Journal of Infectious Diseases|January 15, 2011
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in SwedenPer-Olof Thuresson, Bart Heeg, Benedicte Lescrauwaet, et al.
Plos One|August 11, 2011
Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutralityHelena Skar, Ryan N Gutenkunst, Karin Wilbe Ramsay, et al.
Clinical Immunology (Orlando, Fla.)|May 23, 2008
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirinVeronica D Gonzalez, Karolin Falconer, Jakob Michaëlsson, et al.
Journal of Medical Virology|January 30, 2004
Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A-DAnn Atlas, Tran Thi Thanh Ha, Anna Lindström, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Scandinavian Journal of Infectious Diseases|November 20, 2009
HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatmentKarolin Falconer, Johan K Sandberg, Olle Reichard, et al.
AIDS Research and Human Retroviruses|December 18, 2003
Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AEIrina Maljkovic, Karin Wilbe, Ellen Sölver, et al.
Scandinavian Journal of Infectious Diseases|September 30, 2003
Chronic hepatitis C: updated Swedish consensusRune Wejstål, Annette Alaeus, Björn Fischler, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 21, 2007
Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell functionKarolin Falconer, Veronica D Gonzalez, Olle Reichard, et al.
Scandinavian Journal of Infectious Diseases|July 9, 2010
IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIVKarolin Falconer, Galia Askarieh, Nina Weis, et al.
AIDS Research and Human Retroviruses|March 30, 2005
Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapyAnn Atlas, Fredrik Granath, Anna Lindström, et al.
Scandinavian Journal of Infectious Diseases|January 15, 2011
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in SwedenPer-Olof Thuresson, Bart Heeg, Benedicte Lescrauwaet, et al.
Plos One|August 11, 2011
Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutralityHelena Skar, Ryan N Gutenkunst, Karin Wilbe Ramsay, et al.
Clinical Immunology (Orlando, Fla.)|May 23, 2008
Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirinVeronica D Gonzalez, Karolin Falconer, Jakob Michaëlsson, et al.
Journal of Medical Virology|January 30, 2004
Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A-DAnn Atlas, Tran Thi Thanh Ha, Anna Lindström, et al.
Pageof 2